In other words, the standalone PSMA RPT would have allowed targeting all lesions of a significant volume (≥1 cm3 metabolic tumor volume with any PET tracer) and hypermetabolism (18F-FDG SUVpeak ratio ≥ 1.5) because the 68Ga-PSMA uptake of these lesions would have been significantly above that of the liver (SUVpeak ratio ≥ 1.5). The gene discussed is FOLH1; the disease is neoplasm.